Related references
Note: Only part of the references are listed.Roles of HDAC2 and HDAC8 in Cardiac Remodeling in Renovascular Hypertensive Rats and the Effects of Valproic Acid Sodium
Rui-fang Li et al.
PHARMACOLOGY (2017)
Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma
Francine Foss et al.
CANCER MEDICINE (2017)
Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma
Peter Campbell et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2017)
Emerging drugs for prevention of T-cell mediated rejection in liver and kidney transplantation
Tiffany C. L. Wong et al.
EXPERT OPINION ON EMERGING DRUGS (2017)
Panobinostat for the management of multiple myeloma
Dharshan Sivaraj et al.
FUTURE ONCOLOGY (2017)
Janus kinase inhibition for immunosuppression in solid organ transplantation: Is there a role in complex immunologic challenges?
Cody A. Moore et al.
HUMAN IMMUNOLOGY (2017)
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
Yuankai Shi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Medicinal Chemistry Insights into Novel HDAC Inhibitors: An Updated Patent Review (2012-2016)
Peng Zhan et al.
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2017)
Inhibition of Spleen Tyrosine Kinase Reduces Renal Allograft Injury in a Rat Model of Acute Antibody-Mediated Rejection in Sensitized Recipients
Sharmila Ramessur Chandran et al.
TRANSPLANTATION (2017)
Regulation of Clinical XenotransplantationTime for a Reappraisal
David K. C. Cooper et al.
TRANSPLANTATION (2017)
Chidamide in the treatment of peripheral T-cell lymphoma
Thomas S. Chan et al.
ONCOTARGETS AND THERAPY (2017)
Design, Synthesis, and Biological Evaluation of the First c-Met/HDAC Inhibitors Based on Pyridazinone Derivatives
Dong Lu et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
Immunosuppression for kidney transplantation: Where are we now and where are we going?
Mary Ann Lim et al.
TRANSPLANTATION REVIEWS (2017)
Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer
Christos Damaskos et al.
ANTICANCER RESEARCH (2017)
Structural insights of SmKDAC8 inhibitors: Targeting Schistosoma epigenetics through a combined structure-based 3D QSAR, in vitro and synthesis strategy
Flavio Ballante et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2017)
Propofol postconditioning attenuates hippocampus ischemia-reperfusion injury via modulating JAK2/STAT3 pathway in rats after autogenous orthotropic liver transplantation
Jia Lili et al.
BRAIN RESEARCH (2017)
Why Hydroxamates May Not Be the Best Histone Deacetylase InhibitorsWhat Some May Have Forgotten or Would Rather Forget?
Sida Shen et al.
CHEMMEDCHEM (2016)
Identification of HDAC6-Selective Inhibitors of Low Cancer Cell Cytotoxicity
Irina N. Gaisina et al.
CHEMMEDCHEM (2016)
Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL
Sima Rozati et al.
CLINICAL CANCER RESEARCH (2016)
Interferon Gamma and Contact-dependent Cytotoxicity Are Each Rate Limiting for Natural Killer Cell-Mediated Antibody-dependent Chronic Rejection
C. M. Lin et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2016)
Synthesis of a selective HDAC6 inhibitor active in neuroblasts
Vincent Zwick et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
Inhibitors of histone deacetylase as antitumor agents: A critical review
Mohammed Manal et al.
BIOORGANIC CHEMISTRY (2016)
Romidepsin for the treatment of relapsed/refractory cutaneous T-cell lymphoma (mycosis fungoides/Sezary syndrome): Use in a community setting
Sunil A. Reddy
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Safety of mTOR inhibitors in adult solid organ transplantation
Pedro Ventura-Aguiar et al.
EXPERT OPINION ON DRUG SAFETY (2016)
Panobinostat for the treatment of acute myelogenous leukemia
Fortunato Morabito et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2016)
Valproic Acid and Other HDAC Inhibitors Upregulate FGF21 Gene Expression and Promote Process Elongation in Glia by Inhibiting HDAC2 and 3
Yan Leng et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2016)
Targeting Sirtuin-1 prolongs murine renal allograft survival and function
Matthew H. Levine et al.
KIDNEY INTERNATIONAL (2016)
Panobinostat: A Review in Relapsed or Refractory Multiple Myeloma
Sarah L. Greig
TARGETED ONCOLOGY (2016)
Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients
Julio Pascual et al.
TRANSPLANT INFECTIOUS DISEASE (2016)
Isoform-Selective HDAC Inhibitor Therapy for Transplantation: Are We Ready for HDAC6?
Wayne W. Hancock
TRANSPLANTATION (2016)
Inhibition of Histone Deacetylase 6 Reveals a Potent Immunosuppressant Effect in Models of Transplantation
Jonathan D. Ellis et al.
TRANSPLANTATION (2016)
Modulation of Donor-Specific Antibody Production After Organ Transplantation by Valproic Acid: A Histone Deacetylase Inhibitor
Junsheng Ye et al.
TRANSPLANTATION (2016)
Recent Advances in Mammalian Target of Rapamycin Inhibitor Use in Heart and Lung Transplantation
Nowell M. Fine et al.
TRANSPLANTATION (2016)
The impact of HLA Class I-Specific Killer Cell immunoglobulin-Like Receptors on Antibody-Dependent Natural Killer Cell-Mediated Cytotoxicity and Organ Allograft Rejection
Raja Rajalingam
FRONTIERS IN IMMUNOLOGY (2016)
Panobinostat in multiple myeloma
Morie A. Gertz
LANCET HAEMATOLOGY (2016)
Vorinostat for Refractory or Relapsing Epidermotropic T-cell Lymphoma: A Retrospective Cohort Study of 15 Patients
Anne Kogge et al.
ACTA DERMATO-VENEREOLOGICA (2015)
Class-Specific Histone/Protein Deacetylase Inhibition Protects Against Renal Ischemia Reperfusion Injury and Fibrosis Formation
M. H. Levine et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2015)
Nucleolar Translocation of Histone Deacetylase 2 Is Involved in Regulation of Transcriptional Silencing in the Cat Germinal Vesicle
Pei-Chih Lee et al.
BIOLOGY OF REPRODUCTION (2015)
Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data
Susan E. Bates et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Sirtuin Inhibition Induces Apoptosis-like Changes in Platelets and Thrombocytopenia
Sharda Kumari et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
15 years of ATTEMPTS: Amacromolecular drug delivery systembased on the CPP-mediated intracellular drug delivery and antibody targeting
Junxiao Ye et al.
JOURNAL OF CONTROLLED RELEASE (2015)
Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities
Yiwu Yao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders (vol 13, pg 673, 2014)
Katrina J. Falkenberg et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Romidepsin for the Treatment of Peripheral T-Cell Lymphoma
Swaminathan P. Iyer et al.
ONCOLOGIST (2015)
Epigenetic enzymes are the therapeutic targets for CD4+CD25+/highFoxp3+ regulatory T cells
Jahaira Lopez-Pastrana et al.
TRANSLATIONAL RESEARCH (2015)
The need for minimization strategies: current problems of immunosuppression
Jamal Bamoulid et al.
TRANSPLANT INTERNATIONAL (2015)
Thiol-Based Potent and Selective HDAC6 Inhibitors Promote Tubulin Acetylation and T-Regulatory Cell Suppressive Function
Mariana C. F. Segretti et al.
ACS MEDICINAL CHEMISTRY LETTERS (2015)
Manipulation of B-cell responses with histone deacetylase inhibitors
Michaela Waibel et al.
NATURE COMMUNICATIONS (2015)
A brief history of clinical xenotransplantation
David K. C. Cooper et al.
INTERNATIONAL JOURNAL OF SURGERY (2015)
Specific Inhibition of Histone Deacetylase 8 Reduces Gene Expression and Production of Proinflammatory Cytokines in Vitro and in Vivo
Suzhao Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review
Ahmed Sawas et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2015)
Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors
Toshihiko Tashima et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2014)
Design, Synthesis and Biological Evaluation of Nitro Oxide Donating N-Hydroxycinnamamide Derivatives as Histone Deacetylase Inhibitors
Shiliang Tu et al.
CHEMICAL & PHARMACEUTICAL BULLETIN (2014)
Sirtuin inhibitor Ex-527 causes neural tube defects, ventral edema formations, and gastrointestinal malformations in Xenopus laevis embryos
Yoshihisa Ohata et al.
DEVELOPMENT GROWTH & DIFFERENTIATION (2014)
FoxP3 provides competitive fitness to CD4+CD25+ T cells in leprosy patients via transcriptional regulation
Sudhir Kumar et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2014)
Dendritic cell development requires histone deacetylase activity
Heike Chauvistre et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2014)
New and emerging HDAC inhibitors for cancer treatment
Alison C. West et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Identification of a Novel Aminotetralin Class of HDAC6 and HDAC8 Selective Inhibitors
Guozhi Tang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
VPA inhibits renal cancer cell migration by targeting HDAC2 and down-regulating HIF-1α
Feng-qiang Yang et al.
MOLECULAR BIOLOGY REPORTS (2014)
Effects of histone deacetylase inhibitors on alloresponses
Wayne W. Hancock
LANCET ONCOLOGY (2014)
Valproic acid, but not levetiracetam, selectively decreases HDAC7 and HDAC2 expression in human ovarian cancer cells
Patrycja Kwiecinska et al.
TOXICOLOGY LETTERS (2014)
Improving allogeneic islet transplantation by suppressing Th17 and enhancing Treg with histone deacetylase inhibitors
Koji Sugimoto et al.
TRANSPLANT INTERNATIONAL (2014)
HDAC inhibitors and immunotherapy; a double edged sword?
Michiel Kroesen et al.
ONCOTARGET (2014)
Sirtuin-1 and HIV-1: An Overview
Marilia Rita Pinzone et al.
CURRENT DRUG TARGETS (2013)
Panobinostat activity in both bexarotene-exposed and -naive patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial
Madeleine Duvic et al.
EUROPEAN JOURNAL OF CANCER (2013)
Panobinostat in lymphoid and myeloid malignancies
Amit Khot et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2013)
Tubastatin, a selective histone deacetylase 6 inhibitor shows anti-inflammatory and anti-rheumatic effects
Santosh Vishwakarma et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2013)
Small Molecule Inhibitors of Zinc-dependent Histone Deacetylases
Florence F. Wagner et al.
NEUROTHERAPEUTICS (2013)
SAHA, an HDAC Inhibitor, Attenuates Antibody-Mediated Allograft Rejection
Xin Zhang et al.
TRANSPLANTATION (2013)
Effects of Trichostatin A in a Rat Model of Acute Graft-Versus-Host Disease After Liver Transplantation
Xuefeng Xia et al.
TRANSPLANTATION (2013)
Epigenetic regulation of inflammation: progressing from broad acting histone deacetylase (HDAC) inhibitors to targeting specific HDACs
Melissa D. Cantley et al.
INFLAMMOPHARMACOLOGY (2013)
The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients
Michael J. Kelly-Sell et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity
Zhi-Qiang Ning et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Combination of isoform-selective histone/protein deacetylase inhibitors improves Foxp3+T-regulatory cell function
Ulf H. Beier et al.
CELL CYCLE (2012)
SAHA, an HDAC inhibitor, synergizes with tacrolimus to prevent murine cardiac allograft rejection
Xin Zhang et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2012)
Histone deacetylase inhibitors promote mice corneal allograft survival through alteration of CD4+ effector T cells and induction of Foxp3+ regulatory T cells
Xuming Guo et al.
CELLULAR IMMUNOLOGY (2012)
Histone Deacetylase Inhibition by Sodium Valproate Regulates Polarization of Macrophage Subsets
Chenming Wu et al.
DNA AND CELL BIOLOGY (2012)
Loss of Epigenetic Modification Driven by the Foxp3 Transcription Factor Leads to Regulatory T Cell Insufficiency
Matthew L. Bettini et al.
IMMUNITY (2012)
HDAC inhibitors: modulating leukocyte differentiation, survival, proliferation and inflammation
Matthew J. Sweet et al.
IMMUNOLOGY AND CELL BIOLOGY (2012)
HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications
Omar Khan et al.
IMMUNOLOGY AND CELL BIOLOGY (2012)
Three Novel Acetylation Sites in the Foxp3 Transcription Factor Regulate the Suppressive Activity of Regulatory T Cells
Hye-Sook Kwon et al.
JOURNAL OF IMMUNOLOGY (2012)
Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition
Reinhard Dummer et al.
LEUKEMIA & LYMPHOMA (2012)
Histone Deacetylases 6 and 9 and Sirtuin-1 Control Foxp3+ Regulatory T Cell Function Through Shared and Isoform-Specific Mechanisms
Ulf H. Beier et al.
SCIENCE SIGNALING (2012)
The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells
C. E. Tiffon et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
Histone/protein deacetylases control Foxp3 expression and the heat shock response of T-regulatory cells
Ulf H. Beier et al.
CURRENT OPINION IN IMMUNOLOGY (2011)
Belinostat: clinical applications in solid tumors and lymphoma
L. Rhoda Molife et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
HDAC Inhibition in Lupus Models
Christopher M. Reilly et al.
MOLECULAR MEDICINE (2011)
HDAC Inhibition and Graft Versus Host Disease
Sung Choi et al.
MOLECULAR MEDICINE (2011)
SAHA Decreases HDAC 2 and 4 Levels In Vivo and Improves Molecular Phenotypes in the R6/2 Mouse Model of Huntington's Disease
Michal Mielcarek et al.
PLOS ONE (2011)
Moving to tolerance: Clinical application of T regulatory cells
Alicia N. McMurchy et al.
SEMINARS IN IMMUNOLOGY (2011)
Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma
Shannon A. Kavanaugh et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2010)
Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis
Roel H. Wilting et al.
EMBO JOURNAL (2010)
Design and synthesis of novel isoxazole-based HDAC inhibitors
Paola Conti et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2010)
Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression
Teppei Yamaguchi et al.
GENES & DEVELOPMENT (2010)
Recruitment of cAMP-response Element-binding Protein and Histone Deacetylase Has Opposite Effects on Glucocorticoid Receptor Gene Transcription
Manjapra Variath Govindan
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Molecular and Therapeutic Potential and Toxicity of Valproic Acid
Sebastien Chateauvieux et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2010)
NAD+-Dependent Histone Deacetylases (Sirtuins) as Novel Therapeutic Targets
Joerg Schemies et al.
MEDICINAL RESEARCH REVIEWS (2010)
Prevention of renal interstitial fibrosis via histone deacetylase inhibition in rats with unilateral ureteral obstruction
Fumitaka Kinugasa et al.
TRANSPLANT IMMUNOLOGY (2010)
Nanoparticles evading the reticuloendothelial system: Role of the supported bilayer
Shyh-Dar Li et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2009)
Clinical Studies of Histone Deacetylase Inhibitors
H. Miles Prince et al.
CLINICAL CANCER RESEARCH (2009)
Zn(II)-dependent histone deacetylase inhibitors: Suberoylanilide hydroxamic acid and trichostatin A
Rachel Codd et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2009)
Cutting Edge: Negative Regulation of Dendritic Cells through Acetylation of the Nonhistone Protein STAT-3
Yaping Sun et al.
JOURNAL OF IMMUNOLOGY (2009)
Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions
Chunaram Choudhary et al.
SCIENCE (2009)
Effect of the immunosuppressant histone deacetylase inhibitor FR276457 in a canine renal transplant model
Fumitaka Kinugasa et al.
TRANSPLANT IMMUNOLOGY (2009)
HDAC-class II specific inhibition involves HDAC proteasome-dependent degradation mediated by RANBP2
Annamaria Scognamiglio et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2008)
Effect of a new immunosuppressant histon deacetylase (HDAC) inhibitor FR276457 in a rat cardiac transplant model
Fumitaka Kinugasa et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2008)
Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain
Matthew J. Bottomley et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity
Anja Schuetz et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Optimization of activity-based probes for proteomic profiling of histone deacetylase complexes
Cleo M. Salisbury et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2008)
Effects of histone deacetylase inhibitor SAHA on effector and FOXP3+regulatory T cells in rhesus Macaques
J. Johnson et al.
TRANSPLANTATION PROCEEDINGS (2008)
Deacetylase inhibition promotes the generation and function of regulatory T cells
Ran Tao et al.
NATURE MEDICINE (2007)
Mechanisms of HDAC inhibitor-induced thrombocytopenia
Hideaki Matsuoka et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2007)
Design and synthesis of cyclopeptide analogues of the potent histone deacetylase inhibitor FR235222
Luigi Gomez-Paloma et al.
CHEMMEDCHEM (2007)
Vorinostat in cutaneous T-CELL lymphoma
Madeleine Duvic et al.
DRUGS OF TODAY (2007)
Histone deacetylase inhibitors affect dendritic cell differentiation and immunogenicity
Alessio Nencioni et al.
CLINICAL CANCER RESEARCH (2007)
Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma
Madeleine Duvic et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2007)
Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma
R. K. Lindemann et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma
Bhupinder S. Mann et al.
CLINICAL CANCER RESEARCH (2007)
Activity-based probes for proteomic profiling of histone deacetylase complexes
Cleo M. Salisbury et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma, (CTCL)
Madeleine Duvic et al.
BLOOD (2007)
FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma
Bhupinder S. Mann et al.
ONCOLOGIST (2007)
Chromatin-remodeling factors allow differentiation of bone marrow cells into insulin-producing cells
Thatava Tayaramma et al.
STEM CELLS (2006)
Histone hyperacetylation is associated with amelioration of experimental colitis in mice
Rainer Glauben et al.
JOURNAL OF IMMUNOLOGY (2006)
Teratogenic effects mediated by inhibition of histone deacetylases: Evidence from quantitative structure activity relationships of 20 valproic acid derivatives
D Eikel et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2006)
Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage
JM Solomon et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Chemistry and biology of chromatin remodeling agents: State of art and future perspectives of HDAC inhibitors
M Rodriquez et al.
CURRENT MEDICINAL CHEMISTRY (2006)
A novel biological assay to detect the active form of TGF-β in urine to monitor renal allograft rejection
E Rogier et al.
KIDNEY INTERNATIONAL (2005)
Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis
S Camelo et al.
JOURNAL OF NEUROIMMUNOLOGY (2005)
Trichostatin A attenuates airway inflammation in mouse asthma model
JH Choi et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2005)
Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect
P Reddy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Histone deacetylases (HDACs): characterization of the classical HDAC family
AJM De Ruijter et al.
BIOCHEMICAL JOURNAL (2003)
Control of regulatory T cell development by the transcription factor Foxp3
S Hori et al.
SCIENCE (2003)
FR235222, a fungal metabolite, is a novel, immunosuppressant that inhibits mammalian histone deacetylase (HDAC) - II. Biological activities in animal models
H Mori et al.
JOURNAL OF ANTIBIOTICS (2003)
Structural basis for the NAD-dependent deacetylase mechanism of Sir2
JH Chang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression
G Lagger et al.
EMBO JOURNAL (2002)
The TCR signalosome: a dynamic structure with expanding complexity
G Werlen et al.
CURRENT OPINION IN IMMUNOLOGY (2002)
Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer
RW Johnstone
NATURE REVIEWS DRUG DISCOVERY (2002)
Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen
CJ Phiel et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Structure of the histone deacetylase SIRT2
MS Finnin et al.
NATURE STRUCTURAL BIOLOGY (2001)
Share Paper
